Arcturus Therapeutics Holdings (ARCT) Research & Development (2018 - 2026)

Arcturus Therapeutics Holdings' Research & Development history runs 9 years deep, the most recent figure standing at $21.5 million for Q1 2026.

• Quarterly Research & Development fell 38.31% year-over-year to $21.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $98.8 million (down 43.99% YoY) and the FY2025 annual result came in at $112.2 million, down 42.5% from the prior year.
• Research & Development was $21.5 million for Q1 2026 at Arcturus Therapeutics Holdings, down from $24.5 million in the prior quarter.
• Across five years, Research & Development topped out at $58.7 million in Q2 2024 and bottomed at $21.5 million in Q1 2026.
• A 5-year average of $39.3 million and a median of $38.2 million in 2022 frame the typical range for Research & Development.
• Annual changes were most pronounced in 2023 — Research & Development surged 37.91% — and 2025, when it tumbled 49.58%.
• Arcturus Therapeutics Holdings' Research & Development stood at $27.0 million in 2022, then soared by 35.73% to $36.6 million in 2023, then gained by 19.55% to $43.8 million in 2024, then slumped by 44.09% to $24.5 million in 2025, then slipped by 12.05% to $21.5 million in 2026.
• Business Quant data shows ARCT's Research & Development at $21.5 million in Q1 2026, $24.5 million in Q4 2025, and $23.3 million in Q3 2025.